NASDAQ: CNXU
Conexeu Sciences Inc.CIK 0002066836 · SIC 3842 · Orthopedic & Prosthetic Supplies
Micro by assets
Assets $7M
as of Oct 25, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (TCBI 10-Q) is open in full — no account needed.
8-K
Filed Oct 27, 2026
· Period ending Oct 21, 2026
Summary not yet generated.
424B3
Filed Oct 21, 2026
Summary not yet generated.
Partner
Trade CNXU commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Oct 20, 2026
· Period ending Oct 15, 2026
Summary not yet generated.
424B3
Filed Sep 15, 2026
Summary not yet generated.
10-Q
Filed Sep 14, 2026
· Period ending Jul 31, 2026
Summary not yet generated.
424B3
Filed Sep 10, 2026
Summary not yet generated.
8-K
Filed Sep 10, 2026
· Period ending Sep 4, 2026
Summary not yet generated.
8-K
Filed Jul 7, 2026
· Period ending Jul 7, 2026
Summary not yet generated.
424B3
Filed Jun 16, 2026
Summary not yet generated.
10-Q
Filed Jun 15, 2026
· Period ending Apr 30, 2026
Summary not yet generated.
8-K
Filed Jun 9, 2026
· Period ending Jun 4, 2026
Summary not yet generated.
8-K
Filed May 15, 2026
· Period ending May 11, 2026
Summary not yet generated.
424B3
Filed May 15, 2026
Summary not yet generated.
424B4
Filed May 11, 2026
Summary not yet generated.
S-1/A
Filed Apr 17, 2026
Summary not yet generated.
S-1/A
Filed Apr 10, 2026
Summary not yet generated.
S-1/A
Filed Apr 6, 2026
Summary not yet generated.
S-1
Filed Nov 28, 2025
Summary not yet generated.
Latest financial statements
From 10-Q filed Sep 14, 2026 (period ending Jul 31, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Statements of Operations (Unaudited)
| Description | Three months ended July 31, 2026 | Three months ended July 31, 2025 | Nine months ended July 31, 2026 | Nine months ended July 31, 2025 |
|---|---|---|---|---|
| OPERATING EXPENSES | ||||
| Advertising and promotion | 105,956 | 21,288 | 126,665 | 48,503 |
| Depreciation and amortization | 5,435 | 6,640 | 23,296 | 10,604 |
| Bank charges | 3,714 | 1,474 | 9,390 | 3,132 |
| Business development | 1,227,253 | 52,166 | 1,410,010 | 146,386 |
| Consulting | 3,784,642 | 465,361 | 5,446,548 | 661,957 |
| Filing and listing fees | 100,430 | 9,363 | 125,689 | 9,513 |
| Insurance | 164,457 | 4,148 | 172,857 | 4,148 |
| Investor relations | 26,360 | - | 33,042 | - |
| Management and directors' salaries and fees related parties | 1,512,974 | 457,231 | 2,848,679 | 750,033 |
| Office and general administrative | 34,647 | 1,282 | 58,490 | 7,632 |
| Professional fees | 216,588 | 114,872 | 809,307 | 216,219 |
| Regulatory fees | 235,505 | 29,134 | 328,149 | 29,134 |
| Research and development | 270,412 | 134,662 | 399,578 | 200,795 |
| Total operating expenses | 7,688,373 | 1,297,621 | 11,791,700 | 2,088,056 |
| LOSS FROM OPERATIONS | (7,688,373) | (1,297,621) | (11,791,700) | (2,088,056) |
| OTHER INCOME (EXPENSES) | ||||
| Gain on conversion of payables | - | - | - | 43,176 |
| Write-off of deferred offering costs | (73,169) | - | (73,169) | - |
| Interest income | 34,214 | 386 | 129,800 | 386 |
| Interest expense | - | 43 | - | (4,949) |
| Foreign exchange gain (loss) | 1,677 | (1,378) | (13,688) | 2,759 |
| Total other income (expenses) | (37,278) | (949) | 42,943 | 41,372 |
| LOSS BEFORE TAXES | (7,725,651) | (1,298,570) | (11,748,757) | (2,046,684) |
| Income tax benefit (expense) | - | - | - | - |
| NET LOSS | (7,725,651) | (1,298,570) | (11,748,757) | (2,046,684) |
| Net loss per common share, basic and diluted | (0.29) | (0.09) | (0.52) | (0.19) |
| Weighted average of common shares outstanding, basic and diluted | 26,971,608 | 14,101,995 | 22,725,622 | 10,861,432 |
Condensed Balance Sheets
| Description | July 31, 2026 | October 31, 2025 |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | 1,971,408 | 4,808,965 |
| Restricted cash | 238,208 | 25,155 |
| Share subscription receivable | - | 2,000,000 |
| Tax receivable | - | 3,037 |
| Interest receivable | 2,426 | - |
| Convertible note receivable | - | 71,326 |
| Prepaid expenses | 4,544,274 | 549,930 |
| TOTAL CURRENT ASSETS | 6,756,316 | 7,458,413 |
| NON-CURRENT ASSETS | ||
| Deferred offering costs | - | 42,177 |
| Investment, at cost | 71,328 | - |
| Security deposit | 18,475 | - |
| Operating lease Right of Use, net of accumulated amortization of $9,841 and $0, respectively | 71,641 | - |
| Fixed assets, net of accumulated depreciation of $16,195 and $7,431, respectively | 74,318 | 11,237 |
| Patent, net of accumulated amortization of $22,707 and $9,819, respectively | 163,996 | 176,884 |
| TOTAL ASSETS | 7,156,074 | 7,688,711 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 784,158 | 256,296 |
| Accounts payable and accrued liabilities related parties | 45,374 | - |
| Wages payable | - | 76,000 |
| Lease liability | 39,249 | - |
| Insurance funding agreement | 377,598 | - |
| Liabilities to be settled with shares | 22,350 | - |
| Due to shareholders | 3,722 | 3,722 |
| TOTAL CURRENT LIABILITIES | 1,272,451 | 336,018 |
| LONG-TERM LIABILITIES | ||
| Non-current lease liability | 33,233 | - |
| TOTAL LIABILITIES | 1,305,684 | 336,018 |
| COMMITMENTS AND CONTINGENCIES (See Notes 8 and 9) | ||
| SHAREHOLDERS' EQUITY | ||
| Preferred Stock, par value $0.001, 50,000,000 shares authorized, 0 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively | - | - |
| Common Stock, par value $0.001, 250,000,000 shares authorized, 27,397,164 and 18,906,066 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively | 27,397 | 18,906 |
| Additional paid-in capital | 22,093,270 | 11,855,307 |
| Accumulated deficit | (16,270,277) | (4,521,520) |
| TOTAL SHAREHOLDERS' EQUITY | 5,850,390 | 7,352,693 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 7,156,074 | 7,688,711 |
Statements of Cash Flows (Unaudited)
| Description | Nine months ended July 31, 2026 | Nine months ended July 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (11,748,757) | (2,046,684) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization expense | 12,888 | 5,477 |
| Depreciation expense | 10,408 | 5,127 |
| Fixed asset, disposed | 2,740 | - |
| Gain on conversion of payables | - | (43,176) |
| Warrants issued for services | - | 263,453 |
| Warrants issued to related parties | - | 149,374 |
| Options issued for services | 1,493,977 | - |
| Shares issued for services | 3,081,289 | 480,496 |
| Loss on write-off of offering costs | 73,169 | - |
| Operating lease right of use | 9,841 | - |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued liabilities | 524,865 | 1,785 |
| Accounts payable and accrued liabilities related parties | 45,374 | - |
| Interest receivable | (2,426) | - |
| Taxes receivable | 3,037 | (11,962) |
| Wages payable | (76,000) | - |
| Prepaid expenses | (3,524,559) | (42,300) |
| Security deposit | (18,475) | - |
| Lease liability | (9,000) | - |
| Liability to be settle by shares | 22,350 | - |
| Net cash used in operating activities | (10,099,279) | (1,238,410) |
| Cash flow from investing activities | ||
| Purchase of fixed assets | (76,229) | (18,668) |
| Change in convertible note receivables | (2) | - |
| Loan receivable | - | (40,386) |
| Net cash used in investing activities | (76,231) | (59,054) |
| Cash flow from financing activities | ||
| Receivable form issuance of private placement shares | 2,000,000 | - |
| Repayments on due to shareholders | - | (4,189) |
| Proceeds for shares issued under the warrant inducement program | 2,720,561 | - |
| Proceeds for warrants issued under the warrant inducement program | 5,526 | - |
| Proceeds received for performance warrants exercised | 1,750 | - |
| Proceeds from private placement, net of issuance costs | 2,943,351 | 2,018,413 |
| Repayments on insurance funding agreement | (92,187) | - |
| Repayment of loan payable | - | (94,206) |
| Offering costs paid for future offering | (30,992) | (99,627) |
| Net cash provided by financing activities | 7,548,009 | 1,820,391 |
| Effect of exchange rate changes on cash | 2,997 | (4,415) |
| Increase in cash, cash equivalents and restricted cash | (2,627,501) | 522,927 |
| Cash, cash equivalents and restricted cash at beginning of period | 4,834,120 | 314,616 |
| Cash, cash equivalents and restricted cash at end of period | 2,209,616 | 833,128 |
| Supplemental cash flow information | ||
| Cash paid for interest | - | 17,547 |
| Cash paid for taxes | - | - |
| Non-cash investing and financing activities | ||
| Shares issued for prepaid expenses | - | 353,262 |
| Warrants issued for services to be expensed | - | 218,724 |
| Investment | 71,328 | - |
| Prepaid insurance from funding agreement | 469,785 | - |
| New right of use addition | 81,482 | - |
| Shares issued for conversion of payables | - | 122,897 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗